These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 25433360)

  • 21. Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma.
    Cornell RF; Ky B; Weiss BM; Dahm CN; Gupta DK; Du L; Carver JR; Cohen AD; Engelhardt BG; Garfall AL; Goodman SA; Harrell SL; Kassim AA; Jadhav T; Jagasia M; Moslehi J; O'Quinn R; Savona MR; Slosky D; Smith A; Stadtmauer EA; Vogl DT; Waxman A; Lenihan D
    J Clin Oncol; 2019 Aug; 37(22):1946-1955. PubMed ID: 31188726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
    Nooka AK
    Oncology (Williston Park); 2013 Dec; 27 Suppl 3():11-8. PubMed ID: 25184231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence and management of renal adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
    Shah JJ
    Oncology (Williston Park); 2013 Dec; 27 Suppl 3():19-23. PubMed ID: 25184232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
    Muchtar E; Gatt ME; Rouvio O; Ganzel C; Chubar E; Suriu C; Tadmor T; Shevetz O; Lavi N; Shochat T; Cohen YC; Avivi I; Raanani P; Magen H
    Br J Haematol; 2016 Jan; 172(1):89-96. PubMed ID: 26567759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.
    Stewart AK
    Future Oncol; 2015; 11(15):2121-36. PubMed ID: 26125319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infection risk with carfilzomib in multiple myeloma: a systematic review and meta-analysis of randomised controlled trials.
    Wongsaengsak S; Kopel J; Behera TR; Chakraborty R; Ball S
    Br J Haematol; 2020 Jul; 190(2):e95-e97. PubMed ID: 32400886
    [No Abstract]   [Full Text] [Related]  

  • 27. Carfilzomib Induced Tumor Lysis Syndrome and Other Adverse Events.
    Sandy EB; Weerasinghe C; Terjanian T
    J Pharm Pract; 2020 Apr; 33(2):213-216. PubMed ID: 30278813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.
    Siegel D; Martin T; Nooka A; Harvey RD; Vij R; Niesvizky R; Badros AZ; Jagannath S; McCulloch L; Rajangam K; Lonial S
    Haematologica; 2013 Nov; 98(11):1753-61. PubMed ID: 23935022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carfilzomib-induced Thrombotic Microangiopathy: A Case Based Review.
    Jindal N; Jandial A; Jain A; Lad D; Prakash G; Khadwal A; Nada R; Sethi J; Ahluwalia J; Malhotra P
    Hematol Oncol Stem Cell Ther; 2023 May; 16(4):426-431. PubMed ID: 32735793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies.
    Jakubowiak AJ; DeCara JM; Mezzi K
    Hematology; 2017 Dec; 22(10):585-591. PubMed ID: 28545322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange.
    Sullivan MR; Danilov AV; Lansigan F; Dunbar NM
    J Clin Apher; 2015 Oct; 30(5):308-10. PubMed ID: 25413611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of carfilzomib in the treatment of multiple myeloma.
    Khan RZ; Badros A
    Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring.
    Chari A; Hajje D
    BMC Cancer; 2014 Dec; 14():915. PubMed ID: 25471129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carfilzomib: A Tale of a Heartbreaking Moment: Case Report and Concise Review of the Literature.
    Serra W; Fantin A; Longo C; Rabia G; De Rosa F; Plenteda C; Re F; Crisafulli E; Chetta A
    Cardiovasc Hematol Disord Drug Targets; 2019; 19(3):253-258. PubMed ID: 30516116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Managing adverse events of multiple myeloma and anti-multiple myeloma treatment: a perspective on carfilzomib.
    Siegel DS
    Oncology (Williston Park); 2013 Dec; 27 Suppl 3():2-3. PubMed ID: 25184229
    [No Abstract]   [Full Text] [Related]  

  • 36. Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the "real world".
    Mian HS; Fiala MA; Sanchez L; Vij R; Wildes TM
    Ann Hematol; 2021 May; 100(5):1261-1266. PubMed ID: 33475778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
    Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
    Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular Toxicity of Proteasome Inhibitors in Multiple Myeloma Therapy.
    Zheng Y; Huang S; Xie B; Zhang N; Liu Z; Tse G; Liu T
    Curr Probl Cardiol; 2023 Mar; 48(3):101536. PubMed ID: 36481392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma.
    Pautasso C; Bringhen S; Cerrato C; Magarotto V; Palumbo A
    Expert Opin Drug Metab Toxicol; 2013 Oct; 9(10):1371-9. PubMed ID: 23834482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular Complications of Proteasome Inhibitors Used in Multiple Myeloma.
    Cole DC; Frishman WH
    Cardiol Rev; 2018; 26(3):122-129. PubMed ID: 29077585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.